The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Functional Independence Measure (FIM)
研究概览
简要总结
Astragalus membranaceus (AM) is used to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. PG2, a sterile powder of polysaccharides isolated from the root of astragulus (Huang-Chi) for intravenous injection, has been approved as a botanical drug by TFDA. Hemorrhagic stroke will induce secondary peri-blood clot edema and that may increase intracranial pressure to exacerbate clinical symptom. Therefore, the purpose of the present study was to investigate the efficacy of PG2 on hemorrhagic stroke.
详细描述
This will be a double-blind, randomized, placebo-controlled study. An estimated 60 (at least 48 evaluable) first hemorrhagic stroke patients will be randomly divided into the control and treatment groups. Each group will be treated as follows: 1) control group will accept placebo t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.; 2) treatment group will accept PG2 t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment. Inflammatory index including the levels of C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), S-100 protein, IL-1, IL-6, and TNF-beta levels will be measured and clinical symptoms including Glasgow outcome scale (GOS), modified rankin scale (MRS), Functional Independence Measure (FIM) and Barthel Index (BI) will be evaluated during this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who confirmed diagnosis of first spontaneous hemorrhagic stroke
- •Patients with hemorrhagic stroke in Putamen
- •Patients who admitted to the hospital within 24 hours of onset of hemorrhagic stroke
- •Patients who signed the informed consent form
排除标准
- •Patient with hemorrhage in the area out of Putamen or primary subarachnoid hemorrhage, Arteriovenous malformation (AVM) or brain tumor hemorrhage
- •Patient who performed craniotomy
- •Patient who suffering from cirrhosis, uremia with dialysis, bleeding tendency, severe cardiopulmonary disease or mental disorders would be unable to comply with the study by investigators' decision.
- •Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening.
- •Female patients are pregnant or breast-feeding.
研究组 & 干预措施
PG2 Injection
Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
干预措施: PG2 (Drug)
Placebo
Powder for Injection, 500 ml normal saline, tiw, 2 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Functional Independence Measure (FIM)
时间窗: FIM will be evaluated on day 1 (baseline, before study drug treatment), day 7, day 28 and day 84.
次要结局
- Inflammatory index including C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), S-100 protein, IL-1, IL-6, and TNF-beta levels.(These index will be detected on day 1 (baseline, before study drug treatment), day 4 and day 7.)
- Other clinical symptoms including Glasgow outcome scale (GOS), modified rankin scale (MRS), and Barthel Index (BI)(These clinical symptoms will be evaluated on on day 1 (baseline, before study drug treatment), day 7, day 28 and day 84.)